AIM: To study the value of serum biomarker tests to differentiate between patients with healthy or diseased stomach mucosa: i.e. those with Helicobacter pylori (H pylori) gastritis or atrophic gastritis, who have a high risk of gastric cancer or peptic ulcer diseases. METHODS: Among 162 Japanese outpatients, pepsinogen I (Pg I) and II (Pg II) were measured using a conventional Japanese technique, and the European GastroPanel examination (Pg I and Pg II, gastrin-17 and H pylori antibodies). Gastroscopy with gastric biopsies was performed to classify the patients into those with healthy stomach mucosa, H pylori non-atrophic gastritis or atrophic gastritis. RESULTS: Pg I and Pg II assays with the GastroPanel and the Japanese method showed a highly significant correlation. For methodological reasons, however, serum Pg I, but not Pg II, was twice as high with the GastroPanel test as with the Japanese test. The biomarker assays revealed that 5% of subjects had advanced atrophic corpus gastritis which was also verified by endoscopic biopsies. GastroPanel examination revealed an additional seven patients who had either advanced atrophic gastritis limited to the antrum or antrum-predominant H pylori gastritis. When compared to the endoscopic biopsy findings, the GastroPanel examination classified the patients into groups with "healthy" or "diseased" stomach mucosa with 94% accuracy, 95% sensitivity and 93% specificity. CONCLUSION: Serum biomarker tests can be used to differentiate between subjects with healthy and diseased gastric mucosa with high accuracy.
AIM: To study the value of serum biomarker tests to differentiate between patients with healthy or diseased stomach mucosa: i.e. those with Helicobacter pylori (H pylori) gastritis or atrophic gastritis, who have a high risk of gastric cancer or peptic ulcer diseases. METHODS: Among 162 Japanese outpatients, pepsinogen I (Pg I) and II (Pg II) were measured using a conventional Japanese technique, and the European GastroPanel examination (Pg I and Pg II, gastrin-17 and H pylori antibodies). Gastroscopy with gastric biopsies was performed to classify the patients into those with healthy stomach mucosa, H pylorinon-atrophic gastritis or atrophic gastritis. RESULTS: Pg I and Pg II assays with the GastroPanel and the Japanese method showed a highly significant correlation. For methodological reasons, however, serum Pg I, but not Pg II, was twice as high with the GastroPanel test as with the Japanese test. The biomarker assays revealed that 5% of subjects had advanced atrophic corpus gastritis which was also verified by endoscopic biopsies. GastroPanel examination revealed an additional seven patients who had either advanced atrophic gastritis limited to the antrum or antrum-predominant H pylori gastritis. When compared to the endoscopic biopsy findings, the GastroPanel examination classified the patients into groups with "healthy" or "diseased" stomach mucosa with 94% accuracy, 95% sensitivity and 93% specificity. CONCLUSION: Serum biomarker tests can be used to differentiate between subjects with healthy and diseased gastric mucosa with high accuracy.
Authors: M I Filipe; N Muñoz; I Matko; I Kato; V Pompe-Kirn; A Jutersek; S Teuchmann; M Benz; T Prijon Journal: Int J Cancer Date: 1994-05-01 Impact factor: 7.396
Authors: Victor D Pasechnikov; Sergey Z Chukov; Sergey M Kotelevets; Alexander N Mostovov; Varvara P Mernova; Maria B Polyakova Journal: World J Gastroenterol Date: 2004-11-01 Impact factor: 5.742
Authors: F Farinati; F Di Mario; M Plebani; R Cielo; M C Fanton; F Valiante; M Masiero; M De Boni; G Della Libera; A Burlina Journal: Ital J Gastroenterol Date: 1991-05
Authors: P Correa; W Haenszel; C Cuello; D Zavala; E Fontham; G Zarama; S Tannenbaum; T Collazos; B Ruiz Journal: Cancer Res Date: 1990-08-01 Impact factor: 12.701
Authors: T Knight; J Wyatt; A Wilson; S Greaves; D Newell; K Hengels; M Corlett; P Webb; D Forman; J Elder Journal: Br J Cancer Date: 1996-03 Impact factor: 7.640
Authors: Massimo Rugge; Matteo Fassan; Marco Pizzi; Fabio Farinati; Giacomo Carlo Sturniolo; Mario Plebani; David Y Graham Journal: World J Gastroenterol Date: 2011-11-07 Impact factor: 5.742
Authors: Michael B Cook; Sanford M Dawsey; Lena Diaw; Martin J Blaser; Guillermo I Perez-Perez; Christian C Abnet; Philip R Taylor; Demetrius Albanes; Jarmo Virtamo; Farin Kamangar Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-07-20 Impact factor: 4.254
Authors: M Dinis-Ribeiro; M Areia; A C de Vries; R Marcos-Pinto; M Monteiro-Soares; A O'Connor; C Pereira; P Pimentel-Nunes; R Correia; A Ensari; J M Dumonceau; J C Machado; G Macedo; P Malfertheiner; T Matysiak-Budnik; F Megraud; K Miki; C O'Morain; R M Peek; T Ponchon; A Ristimaki; B Rembacken; F Carneiro; E J Kuipers Journal: Virchows Arch Date: 2011-12-22 Impact factor: 4.064
Authors: M Dinis-Ribeiro; M Areia; A C de Vries; R Marcos-Pinto; M Monteiro-Soares; A O'Connor; C Pereira; P Pimentel-Nunes; R Correia; A Ensari; J M Dumonceau; J C Machado; G Macedo; P Malfertheiner; T Matysiak-Budnik; F Megraud; K Miki; C O'Morain; R M Peek; T Ponchon; A Ristimaki; B Rembacken; F Carneiro; E J Kuipers Journal: Endoscopy Date: 2011-12-23 Impact factor: 10.093
Authors: William L Neumann; Elizabeth Coss; Massimo Rugge; Robert M Genta Journal: Nat Rev Gastroenterol Hepatol Date: 2013-06-18 Impact factor: 46.802
Authors: V Ojetti; R Persiani; F C M Cananzi; C Sensi; A C Piscaglia; N Saulnier; A Biondi; A Gasbarrini; D D'Ugo Journal: World J Surg Date: 2014-08 Impact factor: 3.352